| First Author | Hawkins NA | Year | 2024 |
| Journal | Mamm Genome | Volume | 35 |
| Issue | 3 | Pages | 334-345 |
| PubMed ID | 38862622 | Mgi Jnum | J:359231 |
| Mgi Id | MGI:7782777 | Doi | 10.1007/s00335-024-10046-3 |
| Citation | Hawkins NA, et al. (2024) Fine mapping and candidate gene analysis of Dravet syndrome modifier loci on mouse chromosomes 7 and 8. Mamm Genome 35(3):334-345 |
| abstractText | Dravet syndrome is a developmental and epileptic encephalopathy (DEE) characterized by intractable seizures, comorbidities related to developmental, cognitive, and motor delays, and a high mortality burden due to sudden unexpected death in epilepsy (SUDEP). Most Dravet syndrome cases are attributed to SCN1A haploinsufficiency, with genetic modifiers and environmental factors influencing disease severity. Mouse models with heterozygous deletion of Scn1a recapitulate key features of Dravet syndrome, including seizures and premature mortality; however, severity varies depending on genetic background. Here, we refined two Dravet survival modifier (Dsm) loci, Dsm2 on chromosome 7 and Dsm3 on chromosome 8, using interval-specific congenic (ISC) mapping. Dsm2 was complex and encompassed at least two separate loci, while Dsm3 was refined to a single locus. Candidate modifier genes within these refined loci were prioritized based on brain expression, strain-dependent differences, and biological relevance to seizures or epilepsy. High priority candidate genes for Dsm2 include Nav2, Ptpn5, Ldha, Dbx1, Prmt3 and Slc6a5, while Dsm3 has a single high priority candidate, Psd3. This study underscores the complex genetic architecture underlying Dravet syndrome and provides insights into potential modifier genes that could influence disease severity and serve as novel therapeutic targets. |
